Anti-endotoxin properties of cationic host defence peptides and proteins

被引:45
作者
Bowdish, DME [1 ]
Hancock, REW [1 ]
机构
[1] Univ British Columbia, Ctr Microbial Dis & Immun Res, Vancouver, BC V6T 1Z4, Canada
来源
JOURNAL OF ENDOTOXIN RESEARCH | 2005年 / 11卷 / 04期
关键词
host defence peptides; sepsis; immunomodulator; endotoxin;
D O I
10.1179/096805105X37394
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The innate immune system of mammals contains a series of peptides with overall positive charge and an amphipathic structure which have a variety of important properties in host defences. Although these are often termed cationic antimicrobial peptides, they have numerous roles in innate defences in all complex species of life and thus we prefer to refer to them as host defence peptides. These roles include: (i) an ability to kill micro-organisms directly, ranging from bacteria to viruses, fungi, parasites and helminths; (ii) an adjuvant activity in the adaptive response; and (iii) a multiplicity of roles in modulating innate immunity, including an apparent ability to stimulate protective innate immunity while suppressing harmful inflammatory/septic responses. This latter property may be one of the more important activities of these peptides in vivo. Innate immunity is thought to be triggered by the interaction of conserved bacterial components with particular receptors including Toll-like receptors (TLRs) on host cells. However, the initiation of the innate immune response through this route may trigger a pro-inflammatory cascade that is the principle cause of harmful conditions such as sepsis. Since we are exposed to potentially dangerous pathogens on a daily basis, the host response must contain certain checks and balances. We propose that host defence peptides have a role in feed-back modulation of inflammation under normal (low-pathogen exposure) conditions. This review surveys the available information regarding the anti-endotoxic/anti-inflammatory properties of host defence peptides, and will address whether this potential might be exploited for therapeutic benefit in sepsis.
引用
收藏
页码:230 / 236
页数:7
相关论文
共 76 条
[31]   A synthetic peptide derived from bactericidal/permeability-increasing protein neutralizes endotoxin in vitro and in vivo [J].
Jiang, Z ;
Hong, Z ;
Wei, G ;
Gong, XY ;
Lu, GF ;
Lu, YM ;
Xiao, GX .
INTERNATIONAL IMMUNOPHARMACOLOGY, 2004, 4 (04) :527-537
[32]   Leukocyte and endothelial adhesion molecule studies in knockout mice [J].
Kakkar, AK ;
Lefer, DJ .
CURRENT OPINION IN PHARMACOLOGY, 2004, 4 (02) :154-158
[33]   EFFECT OF A RECOMBINANT N-TERMINAL FRAGMENT OF BACTERICIDAL/PERMEABILITY-INCREASING PROTEIN (RBPI(23)) ON CEREBROSPINAL-FLUID INFLAMMATION-INDUCED BY ENDOTOXIN [J].
KARTALIJA, M ;
KIM, Y ;
WHITE, ML ;
NAU, R ;
TUREEN, JH ;
TAUBER, MG .
JOURNAL OF INFECTIOUS DISEASES, 1995, 171 (04) :948-953
[34]   Protective effects of a human 18-kilodalton cationic antimicrobial protein (CAP18)-derived peptide against murine endotoxemia [J].
Kirikae, T ;
Hirata, M ;
Yamasu, H ;
Kirikae, F ;
Tamura, H ;
Kayama, F ;
Nakatsuka, K ;
Yokochi, T ;
Nakano, M .
INFECTION AND IMMUNITY, 1998, 66 (05) :1861-1868
[35]  
Kluger Martin S, 2004, Adv Dermatol, V20, P163
[36]   PROTECTIVE EFFECT OF A RECOMBINANT AMINO-TERMINAL FRAGMENT OF BACTERICIDAL PERMEABILITY-INCREASING PROTEIN IN EXPERIMENTAL ENDOTOXEMIA [J].
KOHN, FR ;
AMMONS, WS ;
HORWITZ, A ;
GRINNA, L ;
THEOFAN, G ;
WEICKMANN, J ;
KUNG, AHC .
JOURNAL OF INFECTIOUS DISEASES, 1993, 168 (05) :1307-1310
[37]  
LARRICK JW, 1994, J IMMUNOL, V152, P231
[38]   HUMAN CAP18 - A NOVEL ANTIMICROBIAL LIPOPOLYSACCHARIDE-BINDING PROTEIN [J].
LARRICK, JW ;
HIRATA, M ;
BALINT, RF ;
LEE, J ;
ZHONG, J ;
WRIGHT, SC .
INFECTION AND IMMUNITY, 1995, 63 (04) :1291-1297
[39]   Interaction and cellular localization of the human host defense peptide LL-37 with lung epithelial cells [J].
Lau, YE ;
Rozek, A ;
Scott, MG ;
Goosney, DL ;
Davidson, DJ ;
Hancock, REW .
INFECTION AND IMMUNITY, 2005, 73 (01) :583-591
[40]   Recombinant bactericidal/permeability-increasing protein (rBPI21) as adjunctive treatment for children with severe meningococcal sepsis:: a randomised trial [J].
Levin, M ;
Quint, PA ;
Goldstein, B ;
Barton, P ;
Bradley, JS ;
Shemie, SD ;
Yeh, T ;
Kim, SS ;
Cafaro, DP ;
Scannon, PJ ;
Giroir, BP .
LANCET, 2000, 356 (9234) :961-967